Blood cancer trials actively recruiting

The following trials are actively recruiting people with blood cancer and are listed with the study identifier number. You can share the study identifier number with your physician or search for more information using the number at clinicaltrials.gov.

  • GO27831: A study of atezolizumab in people with solid tumors or blood cancer.
  • GO29754: A study of atezolizumab in people with bone marrow failure disorder (also called myelodysplastic syndromes or MDS).
  • GO29383: A study of atezolizumab in people with lymphoma and diffuse large B-cell lymphoma.
  • GO29695: A study of atezolizumab in people with multiple myeloma.
  • GO30139: A study of atezolizumab, taken in combination with immunomodulatory agents, in people with acute myeloid leukemia (AML).


Participation in clinical research involves risk. Please visit the 'About Clinical Trials' page of this website for additional information regarding what to consider before enrolling in a clinical trial.

Atezolizumab
Atezolizumab is an investigational antibody (drug).
Placebo (pluh-SEE-boh)
A fake pill or treatment that looks the same and is taken in the same way as a drug or treatment being tested in a clinical trial. It contains no active ingredients. It’s sometimes called a "dummy" pill.
Immunotherapy (IH-myoo-noh-THEYR-uh-pee)
Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect.
Metastatic (meh-tuh-STA-tik)
Has to do with the spread of cancer from the place where it started to other places in the body.
Urothelial (ur-o-THE-li-al)
The urothelium is a layer of tissue that lines the urethra, bladder, ureters, prostate, and renal pelvis. Cancer that begins in the urothelium is called urothelial cancer.
POPLAR GO28753
This global multicenter, open-label, randomized, controlled study will evaluate the safety and efficacy of MPDL3280A (Anti-PD-L1 Antibody) compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Patients will be randomized 1:1 to receive either docetaxel (75 mg/m2 intravenous infusion) or MPDL3280A (1200 mg intravenous infusion) every three weeks. Treatment may continue up to 16 cycles (or 12 months, whichever comes first) in the absence of unacceptable toxicity or disease progression.
Status: Recruitment closed
BIRCH GO28754
This global multicenter, single-arm study will evaluate the efficacy and safety of MPDL3280A in patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer. Patients will receive MPDL3280A 1200 mg intravenously every 3 weeks for a maximum of 16 cycles (or 12 months, whichever occurs first) in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression. Patients who complete the initial treatment stage may be eligible for MPDL3280A re-treatment upon subsequent disease progression during the follow-up period without intervening systemic anti-cancer therapy.
Status: Recruiting
OAK GO28915
This global multicenter, open-label, randomized, controlled study will evaluate the safety and efficacy of MPDL3280A (anti-PD-L1 Antibody) compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Patients will be randomized 1:1 to receive either docetaxel (75 mg/m2 intravenous infusion) or MPDL3280A (1200 mg intravenous infusion) every three weeks. Treatment may continue up to 16 cycles (or 12 months, whichever comes first) in the absence of unacceptable toxicity or disease progression.
Status: Recruiting
FIR GO28625
This global multicenter, single-arm study will evaluate the efficacy and safety of MPDL3280A in patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer. Patients will receive MPDL3280A 1200 mg intravenously every 3 weeks for a maximum of 16 cycles (or 12 months, whichever occurs first) in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression. Patients who complete the initial treatment stage may be eligible for MPDL3280A re-treatment upon subsequent disease progression during the follow-up period without intervening systemic anti-cancer therapy.
Status: Recruiting
GO29293
This phase II, single-arm study was designed to evaluate the effect of MPDL3280A treatment in patients with locally advanced or metastatic urothelial bladder cancer. Patients will be enrolled into 1 of 2 cohorts. Cohort 1 will consist of patients who are treatment-naïve and ineligible for platinum-containing therapy. Cohort 2 will contain patients who have progressed during or following a prior platinum-based chemotherapy regimen. Patients in both cohorts will be given a 1200 mg intravenous (IV) dose of MPDL3280A on Day 1 of 21-day cycles. Treatment may continue for up to 16 cycles or 12 months, whichever is first, in the absence of toxicity or disease progression. Patients will be followed for up for 2 years. Patients who complete the initial treatment stage of up to 16 cycles may be eligible for MPDL3280A re-treatment upon subsequent disease progression during the follow-up period and without intervening systemic anti-cancer therapy.
Status: Recruiting
IMpower 130 GO29537
This randomized Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of MPDL3280A in combination with carboplatin + Nab-paclitaxel compared with treatment with carboplatin + Nab-paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).
Status: Recruiting
IMpower 131 GO29437
This randomized, open-label study will evaluate the safety and efficacy of MPDL3280A in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive patients with Stage IV squamous non-small cell lung cancer (NSCLC).
Status: Recruiting
IMpower 010 GO29527
Study to Assess Safety and Efficacy of Atezolizumab Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer.
The primary efficacy objective of the study is to evaluate the efficacy of 16 cycles of Atezolizumab treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the investigator
Status: Recruiting
WO39392
Study details coming soon.
IMpower 150 GO29436
This randomized, open-label study will evaluate the safety and efficacy of MPDL3280A in combination with carboplatin and paclitaxel with or without bevacizumab compared with treatment with carboplatin plus (+) paclitaxel and bevacizumab in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).
Status: Recruiting
IMpower 111 GO29432
This randomized, open-label study is designed to evaluate and compare the safety and efficacy of MPDL3280A (anti-programmed death ligand 1 [PD-L1] antibody) compared with treatment with gemcitabine + cisplatin or carboplatin in patients with chemotherapy-naive, Stage IV squamous non-small cell lung cancer (NSCLC).
Status: Recruiting
IMpower 110 GO29431
This randomized, open-label study will evaluate the safety and efficacy of MPDL3280A (anti programmed death ligand 1 [PD-L1] antibody) compared with treatment with a platinum-based regimen (carboplatin or cisplatin per investigator discretion) + pemetrexed in PD-L1-selected, chemotherapy-naive patients with Stage IV NSCLC.
Status: Recruiting
GO30140
A study of Atezolizumab, administered in combination with bevacizumab and/or other treatments, in people with solid tumors.
WP29158
This open-label, multicenter study will assess the safety, tolerability, and pharmacokinetics of intravenous (IV) dosing of MPDL3280A and oral dosing of Tarceva (erlotinib) administered in combination to patients with non-small cell lung cancer (NSCLC).
Status: Recruiting
IMvigor 010 WO29636
A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy *Purpose: This study is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with observation in participants with PD-L1-selected muscle-invasive bladder cancer (MIBC) who are at high risk for recurrence following cystectomy.
Status: Recruiting
IMmotion 151 WO29637
This randomized, open-label study is designed to evaluate the efficacy of MPDL3280A (anti-PD-L1 antibody) plus bevacizumab versus sunitinib in patients with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.
Status: Recruiting
IMpassion 130 WO29522
This study is being conducted to determine the efficacy and safety in using MPDL3280A in combination with nab-paclitaxel in treating patients with metastatic breast cancer. The safety of single-agent nab-paclitaxel has been determined in previous studies of patients with metastatic breast cancer, and preliminary data shows the use of MPDL3280A is safe to use in combination with chemotherapy.
Status: Recruiting
GO29695
This multicenter, open-label, Phase I study will evaluate the safety and pharmacokinetics of MPDL3280A alone or in combination with lenalidomide in patients with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). The planned duration of this study is approximately 36 months.
Status: Recruiting
GO29383
This open-label, multicenter, global study is designed to assess the safety, tolerability, and pharmacokinetics of intravenous MPDL3280A and obinutuzumab administered in combination to patients with refractory or relapsed follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The anticipated duration of this study is approximately 44 months.
Status: Recruiting
IMvigor 211 GO29294
This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of MPDL3280A compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 767 patients.
Status: Recruiting
ML29725
An Expanded Access Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.
Status: Recruiting
ML39236
A study of atezolizumab in people with Stage IB, II, or IIIA resectable and untreated non-small cell lung cancer.
Status: Recruiting
ML39237
A study of atezolizumab in people with treatment-naïve locally advanced or metastatic non-small cell lung cancer.
Status: Recruiting
GO29831
A study of the Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer.
Status: Recruiting
MO29518
The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in patients with advanced solid tumors treated with MPDL3280A, defined as the percentage of patients with CR, PR or SD as assessed by the Investigator according to RECIST, v1.1 (except for prostate cancer and malignant pleural mesothelioma) and disease-specific criteria for patients with prostate cancer and malignant pleural mesothelioma.
Status: Recruiting
GO29322
A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting
GO29438
This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous non-small cell lung cancer (NSCLC).
Status: Recruiting
GO30139
The Effect of atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy [IMvigor130]. This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with gemcitabine/carboplatin versus placebo plus gemcitabine/carboplatin in participants with locally advanced or metastatic urothelial carcinoma (UC), who have not received prior systemic therapy and who are ineligible to receive cisplatin-based therapy. Participants will be randomized in a 2:1 ratio (experimental to control arm) to receive either atezolizumab in combination with gemcitabine/carboplatin or to placebo in combination with gemcitabine/carboplatin.
Status: Recruiting
GO29754
A Safety and Pharmacology Study of atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes. This is a non-randomized, open-label, Phase 1 study of atezolizumab (anti-PD-L1 monoclonal antibody [mAb] in intermediate/high/very high-risk myelodysplastic syndromes (MDS) patients, as evaluated by the International Prognostic Scoring System-Revised (IPSS-R). Eligible participants will either have never received treatment with hypomethylating agents(s) (HMAs) or have relapsed or are refractory to prior HMA therapy. The primary objectives of this study are to determine the safety and feasibility of atezolizumab therapy in these patient populations, including treatment in combination with azacitidine.
Status: Recruiting
WO30070
A study of Atezolizumab in people with untreated, locally advanced or metastatic bladder cancer who are ineligible for cisplatin-based therapy.
Status: Recruiting
GO30081
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer [IMpower133].
Status: Recruiting
Before you proceed

The information contained in this section of the site is intended for US healthcare professionals only. Select “OK” if you are a US healthcare professional.

You are leaving the anti-PDL1 clinical trial website:

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc., makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.